Free tool
Rare disease stocks
We cover 4 companies grouped under the Rare disease theme. The median market value in the group is $5.38B. Across the group, the median move over the past trading day is +0.38%. Price change over the past year runs from −15.3% to +210.7% across the middle 80 percent of the group, with a median of −0.0%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
4 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| 0HNC.L | BioMarin Pharmaceutical Inc. | $66.19 | +0.05% | +11.54% | +15.03% |
| 0HI3.L | Arrowhead Pharmaceuticals, Inc. | $89.35 | +3.26% | +32.80% | +294.59% |
| CAMX.ST | Camurus AB (publ) | 615.00 SEK | −1.68% | +0.49% | −15.35% |
| 0RD1.L | Camurus AB (publ) | 609.98 SEK | −0.21% | −0.53% | −15.10% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.